Agenda - Clinical trials information system information day webinar

Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn

Appendix 1: Acceptable intakes established for N-nitrosamines

Timetable: Safety referral (Article 107i, urgent Union procedure)

Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)